These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10745501)

  • 1. Tirofiban-induced coronary thrombolysis.
    Jayasundera TG; Feldman DN; Marmur JD
    J Invasive Cardiol; 1999 Mar; 11(3):138-40. PubMed ID: 10745501
    [No Abstract]   [Full Text] [Related]  

  • 2. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
    Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
    Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: maybe less is more?
    Fischell TA
    Am Heart J; 2006 Nov; 152(5):812-4. PubMed ID: 17070138
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
    Campo G; Valgimigli M; Frangione A; Luccarelli S; Cangiano E; Cavazza C; Fileti L; Ferrari R;
    J Am Coll Cardiol; 2010 Jan; 55(3):255-6. PubMed ID: 20117406
    [No Abstract]   [Full Text] [Related]  

  • 7. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
    van 't Hof AW; Ernst N; de Boer MJ; de Winter R; Boersma E; Bunt T; Petronio S; Marcel Gosselink AT; Jap W; Hollak F; Hoorntje JC; Suryapranata H; Dambrink JH; Zijlstra F;
    Eur Heart J; 2004 May; 25(10):837-46. PubMed ID: 15140531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
    Stepinska J; Banaszewski M; Konopka A; Szajewski T
    Thromb Haemost; 2002 Feb; 87(2):355-6. PubMed ID: 11858506
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban.
    Hölschermann H; Krombach C; Jung A; Jacobi F; Tillmanns H; Weinand F
    Thromb Haemost; 2005 Sep; 94(3):684-6. PubMed ID: 16268493
    [No Abstract]   [Full Text] [Related]  

  • 10. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
    Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
    J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase.
    Meyners W; Peters S; Trümmel M; Koehler B
    Z Kardiol; 2004 May; 93(5):407-12. PubMed ID: 15160277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landmarks: examining the foundation for GP IIb/IIIa inhibitors in PCI.
    J Invasive Cardiol; 2002 Dec; 14(12):776-9. PubMed ID: 12537005
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the use of glycoprotein IIb/IIIa inhibitors in acute myocardial infarction.
    Joseph A
    J Emerg Med; 1999; 17(3):567-73. PubMed ID: 10338258
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of tirofiban for failed thrombolysis during acute myocardial infarction.
    Vetrano A; Carotenuto R; Corsini F; Schioppa M; Martone A; Melorio S; Sideri F; Romano S; Chieffo C; Corsini G
    Am J Cardiol; 2004 Apr; 93(7):914-6. PubMed ID: 15050497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet disaggregation: putting time on your side in acute myocardial infarction.
    Simon DI; Sakuma M
    J Am Coll Cardiol; 2004 Jul; 44(2):324-6. PubMed ID: 15261926
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence.
    Singh S; Gopal AK; Bahl VK
    Indian Heart J; 2005; 57(3):201-9. PubMed ID: 16196176
    [No Abstract]   [Full Text] [Related]  

  • 18. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.